

# Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.3	23.03.2020	2805574-00006	Date of first issue: 18.05.2018

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

: EHSSTEWARD@organon.com

1.1 Product identifier						
Trade name	:	Mirtazapine Solid Formulation				
1.2 Relevant identified uses of the	he s	ubstance or mixture and uses advised against				
Use of the Sub- stance/Mixture	:	Pharmaceutical				
1.3 Details of the supplier of the safety data sheet						
Company	:	Organon & Co. 30 Hudson Street, 33nd floor 07302 Jersey City, New Jersey, U.S.A				
Telephone	:	551-430-6000				

#### 1.4 Emergency telephone number

E-mail address of person

responsible for the SDS

215-631-6999

## **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

## Classification T.R. SEA No 28848

Reproductive toxicity, Category 2

Specific target organ toxicity - repeated exposure, Category 2 Long-term (chronic) aquatic hazard, Category 3

2

## 2.2 Label elements

#### Labelling T.R. SEA No 28848

Hazard pictograms

H361fd: Suspected of damaging fertility. Suspected of damaging the unborn child. H373: May cause damage to organs through prolonged or repeated exposure. H412: Harmful to aquatic life with long lasting effects.

Signal word	:	Warning
Hazard statements	:	H361fd Suspected of damaging fertility. Suspected of damag- ing the unborn child. H373 May cause damage to organs through prolonged or repeated exposure.



# Mirtazapine Solid Formulation

Version 2.3	Revision Date: 23.03.2020	SDS Number: 2805574-00006	Date of last issue: 13.09.2019 Date of first issue: 18.05.2018
		H412 Harmful	to aquatic life with long lasting effects.
Preca	utionary statements	· Prevention:	
		P260 Do not l P273 Avoid re	special instructions before use. breathe dust. elease to the environment. rotective gloves/ protective clothing/ eye protec- ction.
		<b>Response:</b> P308 + P313 attention.	IF exposed or concerned: Get medical advice/
		<b>Storage:</b> P405 Store lo	cked up.

Hazardous components which must be listed on the label:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine

## 2.3 Other hazards

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

## **SECTION 3: Composition/information on ingredients**

## 3.2 Mixtures

## Components

Chemical name	CAS-No. EC-No. Index-No. Registration num- ber	Classification	Concentration (% w/w)
(+/-)-1,2,3,4,10,14b-Hexahydro-2- methylpyrazino[2,1-a]pyrido[2,3- c][2]benzazepine	85650-52-8 288-060-6	Acute Tox.4; H302 Repr.2; H361fd STOT RE2; H373 Aquatic Chronic2; H411	>= 10 - < 20
For explanation of abbreviations see se	ection 16.		

## **SECTION 4: First aid measures**

## 4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection,



# Mirtazapine Solid Formulation

Version 2.3	Revision Date: 23.03.2020	SDS Number: 2805574-00006	Date of last issue: 13.09.2019 Date of first issue: 18.05.2018
			recommended personal protective equipment ential for exposure exists (see section 8).
lf inha	aled	: If inhaled, rer Get medical	move to fresh air. attention.
In ca	se of skin contact	of water. Remove con Get medical Wash clothin	ntact, immediately flush skin with soap and plenty taminated clothing and shoes. attention. g before reuse. lean shoes before reuse.
In cas	se of eye contact		se well with water. attention if irritation develops and persists.
lf swa	allowed	Get medical	DO NOT induce vomiting. attention. thoroughly with water.
4.2 Most i	important symptoms a	nd effects, both a	acute and delayed
Risks	;	unborn child.	f damaging fertility. Suspected of damaging the amage to organs through prolonged or repeated
		exposure.	
		Contact with the skin.	dust can cause mechanical irritation or drying of
		Dust contact	with the eyes can lead to mechanical irritation.
4.3 Indica	tion of any immediate	medical attentior	n and special treatment needed
Treat	ment	: Treat sympto	matically and supportively.
SECTION	N 5: Firefighting mea	sures	
5.1 Exting	guishing media		
	ble extinguishing media	: Water spray Alcohol-resis Carbon dioxi	de (CO2)

Unsuitable extinguishing : None known. media

## 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire- fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a
		potential dust explosion hazard.

Dry chemical



# Mirtazapine Solid Formulation

Ver 2.3	sion	Revision Date: 23.03.2020		OS Number: 05574-00006	Date of last issue: 13.09.2019 Date of first issue: 18.05.2018
	Hazard	lous combustion prod-	:	Exposure to comb	pustion products may be a hazard to health.
5.0	ucts	forfinktor		Silicon oxides	
5.3	Specia	for firefighters I protective equipment	:		e, wear self-contained breathing apparatus.
	for firef	ighters		Use personal prot	tective equipment.
	Specifi ods	c extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do

## **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice and personal protective equip- ment recommendations.

## 6.2 Environmental precautions

Environmental precautions	: Discharge into the environment must be avoided.
	Prevent further leakage or spillage if safe to do so.
	Retain and dispose of contaminated wash water.
	Local authorities should be advised if significant spillages
	cannot be contained.

## 6.3 Methods and material for containment and cleaning up

	Methods for cleaning up	<ul> <li>Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.</li> </ul>
--	-------------------------	--

## 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

According to 13 December 2014, No:29204, "Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I".



# Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.3	23.03.2020	2805574-00006	Date of first issue: 18.05.2018

## **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion.
		Provide adequate precautions, such as electrical grounding
		and bonding, or inert atmospheres.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not breathe dust.
-		Do not swallow.
		Avoid contact with eyes.
		Avoid prolonged or repeated contact with skin.
		Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
		Minimize dust generation and accumulation.
		Keep container closed when not in use.
		Keep away from heat and sources of ignition.
		Take precautionary measures against static discharges.
		Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working
		place. When using do not eat, drink or smoke. Wash contami-
		nated clothing before re-use.
7.2 Conditions for safe storage, i	incl	uding any incompatibilities
Requirements for storage		Keep in properly labelled containers. Store locked up. Store in
areas and containers	•	accordance with the particular national regulations.
Advice on common storage	:	Do not store with the following product types:
Advice on common storage	·	Strong oxidizing agents
7.3 Specific end use(s)		

#### Specific use(s)

: No data available

## **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
(+/-)- 1,2,3,4,10,14b- Hexahydro-2- methylpyra- zino[2,1- a]pyrido[2,3-	85650-52-8	TWA	25 μg/m3	Internal

According to 13 December 2014, No:29204, "Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I".



# Mirtazapine Solid Formulation

Ver 2.3	sion Revisio 23.03.2	on Date: 2020	 Number: 574-00006	 te of last issue: 13.09.20 te of first issue: 18.05.20	
	c][2]benzazepir	ne			
			Wipe limit	250 µg/100 cm <sup>2</sup>	Internal

#### 8.2 Exposure controls

#### **Engineering measures**

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

#### Personal protective equipment

Eye protection	:	Wear the following personal protective equipment: Safety goggles Equipment should conform to TS EN 166
Material	:	Chemical-resistant gloves
Remarks	:	Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous sub- stance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Skin and body protection	:	Select appropriate protective clothing based on chemical re- sistance data and an assessment of the local exposure poten- tial. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
Respiratory protection	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to TS EN 143
Filter type	:	Particulates type (P)

## **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	:	powder No data available No data available No data available
рН	:	No data available
Melting point/freezing point	:	No data available



# Mirtazapine Solid Formulation

Vers 2.3	sion	Revision Date: 23.03.2020		S Number: )5574-00006	Date of last issue: 13.09.2019 Date of first issue: 18.05.2018
		oiling point and boiling	:	No data available	9
	range Flash p	ooint	:	Not applicable	
	Evapor	ation rate	:	No data available	9
	Flamm	ability (solid, gas)	:	May form explos dling or other me	ive dust-air mixture during processing, han- eans.
		explosion limit / Upper bility limit	:	No data available	e
		explosion limit / Lower bility limit	:	No data available	e
	Vapour	pressure	:	No data available	9
	Relativ	e vapour density	:	No data available	9
	Relativ	e density	:	No data available	9
	Density	,	:	No data available	9
		er solubility n coefficient: n-	:	No data available No data available	
	Auto-ig	nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	Viscosi Visc	ty cosity, dynamic	:	No data available	9
	Viso	cosity, kinematic	:	No data available	9
	Explosi	ve properties	:	Not explosive	
	Oxidizii	ng properties	:	The substance o	r mixture is not classified as oxidizing.
9.2 (	Other ir	oformation			
	Flamm	ability (liquids)	:	No data available	9
	Molecu	lar weight	:	No data available	9
	Particle	e size	:	No data available	e

According to 13 December 2014, No:29204, "Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I".



# Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.3	23.03.2020	2805574-00006	Date of first issue: 18.05.2018

## **SECTION 10: Stability and reactivity**

## 10.1 Reactivity

Not classified as a reactivity hazard.

#### **10.2 Chemical stability**

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions	: May form explosive dust-air mixture during processing, han-
	dling or other means.
	Can react with strong oxidizing agents.
10.4 Conditions to avoid	

Conditions to avoid	:	Heat, flames and sparks.
		Avoid dust formation.

## **10.5 Incompatible materials**

Materials to avoid	: Oxidizing agents
--------------------	--------------------

## **10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

## **SECTION 11: Toxicological information**

11.1 Information on toxicological effects					
Information on likely routes of :	Inhalation				

exposure	-	Skin contact
		Ingestion
		Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity

: Acute toxicity estimate: > 2.000 mg/kg Method: Calculation method

#### **Components:**

(+/-)-1,2,3,4,10,14b-Hexahyd	ro-2	2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Acute oral toxicity	:	LD50 (Rat): 320 - 490 mg/kg

## Skin corrosion/irritation

Not classified based on available information.

## Serious eye damage/eye irritation

Not classified based on available information.

According to 13 December 2014, No:29204, "Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I".



# **Mirtazapine Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.3	23.03.2020	2805574-00006	Date of first issue: 18.05.2018

## Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

## **Respiratory sensitisation**

Not classified based on available information.

#### Germ cell mutagenicity

Not classified based on available information.

#### Components:

## (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

	Test Type: Bacterial reverse mutation assay (AMES) Result: negative		
	Test Type: In vitro mammalian cell gene mutation test Test system: Chinese hamster lung cells Result: negative		
	Test Type: unscheduled DNA synthesis assay Test system: mammalian cells Result: negative		
	Test Type: sister chromatid exchange assay Test system: mammalian cells Result: negative		
Genotoxicity in vivo :	Test Type: Micronucleus test Species: Rat Cell type: Bone marrow Application Route: Oral Result: negative		

## Carcinogenicity

Not classified based on available information.

## Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
---

Species Application Route Exposure time LOAEL Result Target Organs	:	Mouse Oral 18 month(s) 200 mg/kg body weight equivocal Liver
Species Application Route Exposure time LOAEL Result	:	Rat Oral 2 Years 20 mg/kg body weight equivocal

According to 13 December 2014, No:29204, "Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I".



# Mirtazapine Solid Formulation

Version 2.3	n Revision Date: 23.03.2020	SDS Number: 2805574-00006	Date of last issue: 13.09.2019 Date of first issue: 18.05.2018
Та	rget Organs	: Liver, Thyroi	d
	productive toxicity spected of damaging ferti	lity. Suspected of c	lamaging the unborn child.
<u>Cc</u>	omponents:		
-			zino[2,1-a]pyrido[2,3-c][2]benzazepine:
Eff	fects on fertility	Species: Ra Application F Fertility: LO/ Symptoms: I tions Result: Anim	
Eff	fects on foetal develop- ent	Result: Emb spring were Test Type: D Species: Ra Application f Developmer	t Route: Oral Ital Toxicity: LOAEL: 100 mg/kg body weight ryotoxic effects and adverse effects on the off- detected., No teratogenic effects Development bbit
	eproductive toxicity - As- ssment	fertility, base	nce of adverse effects on sexual function and ad on animal experiments., Some evidence of cts on development, based on animal experi-

## STOT - single exposure

Not classified based on available information.

## STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

## Components:

## (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Exposure routes	: Ingestion	
Target Organs	: Nervous system	
Assessment	: May cause damage to organs through prolonged or	repeated
	exposure.	



# Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.3	23.03.2020	2805574-00006	Date of first issue: 18.05.2018

## Repeated dose toxicity

#### **Components:**

## (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species	: Rat
LOAEL	: 120 mg/kg
Application Route	: Oral
Exposure time	: 13 Weeks
Target Organs	: Nervous system
Species	: Dog
LOAEL	: 15 mg/kg
Application Route	: Oral
Exposure time	: 52 Weeks
Target Organs	: Nervous system
Symptoms	: Tremors
Species	: Dog
LOAEL	: 20 mg/kg
Application Route	: Oral
Exposure time	: 13 Weeks
Target Organs	: Nervous system, Testis
Symptoms	: Tremors
Exposure time Target Organs Symptoms Species LOAEL Application Route Exposure time Target Organs	<ul> <li>52 Weeks</li> <li>Nervous system</li> <li>Tremors</li> <li>Dog</li> <li>20 mg/kg</li> <li>Oral</li> <li>13 Weeks</li> <li>Nervous system, Test</li> </ul>

#### Aspiration toxicity

Not classified based on available information.

## Experience with human exposure

#### **Components:**

## (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

• • • • • • • •		
Ingestion	: Symptoms: Drowsiness, constipation, dry mouth, asthenia,	
	Dizziness, Disorientation	

## **SECTION 12: Ecological information**

## 12.1 Toxicity

#### Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:			
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 6,92 mg/l Exposure time: 96 h Method: FDA 4.11	
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 19,5 mg/l Exposure time: 48 h	
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 5,7 mg/l	



# Mirtazapine Solid Formulation

Vers 2.3	sion	Revision Date: 23.03.2020		9S Number: 05574-00006	Date of last issue: 13.09.2019 Date of first issue: 18.05.2018	
				Exposure time: 72 Method: OECD Te		
			NOEC (Pseudokirchneriella subcapitata (green alg mg/l Exposure time: 72 h Method: OECD Test Guideline 201			
	Toxicity	v to microorganisms	:	EC50 (Natural mid Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition	
				NOEC (Natural m Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition	
Toxicity to fish (Chronic tox- icity)		:	NOEC: 3,6 mg/l Exposure time: 31 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210			
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)		:	NOEC: 0,32 mg/l Exposure time: 21 Species: Daphnia Method: OECD Te	magna (Water flea)		
12.2 Persistence and degradability No data available						
12.3 Bioaccumulative potential						
	Compo	onents:				
	(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:					
	Bioaccu	umulation	:	Species: Oncorhy Bioconcentration f Method: OECD Te		
	Partition coefficient: n- octanol/water		:	log Pow: 2,78		
12.4	Mobilit	y in soil				
	Components:					
	(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine: Distribution among environ- : log Koc: 4,48 mental compartments				2,1-a]pyrido[2,3-c][2]benzazepine:	

12.5 Results of PBT and vPvB assessment

Not relevant

According to 13 December 2014, No:29204, "Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I".



# Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.3	23.03.2020	2805574-00006	Date of first issue: 18.05.2018

### 12.6 Other adverse effects

No data available

## **SECTION 13: Disposal considerations**

#### **13.1 Waste treatment methods**

Product		Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## **SECTION 14: Transport information**

#### 14.1 UN number

Not regulated as a dangerous good

## 14.2 UN proper shipping name

Not regulated as a dangerous good

## 14.3 Transport hazard class(es)

Not regulated as a dangerous good

## 14.4 Packing group

Not regulated as a dangerous good

## 14.5 Environmental hazards

Not regulated as a dangerous good

## 14.6 Special precautions for user

## Not applicable

## 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks

Not applicable for product as supplied. :

## **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

KKDIK (30105 (Bis)) - Restrictions on the manufacture, : Not applicable placing on the market and use of certain dangerous substances, mixtures and articles (Annex 17) Regulation on Persistent Organic Pollutants (Number : Not applicable 30595) Regulation on prevention of major industrial accidents. Reg number 30702 Not applicable



# Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.3	23.03.2020	2805574-00006	Date of first issue: 18.05.2018

#### Other regulations:

According to 13 December 2014, No:29204, "Ministry of Environment and Urbanization; Regulation on Safety data sheets regarding hazardous substances and mixtures; Part I". Regulation on Classification, Labelling and Packaging of Substances and Mixtures. Dated 11 December 2013, Numbered 28848 (Bis) Ministry of Environment and Forestry. Regulation on Health and Safety Measures Of Working with Chemicals Substances Dated 12.08.13, numbered 28733 Ministry of Labour and Social Security.

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

## **SECTION 16: Other information**

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H302	:	Harmful if swallowed.
H361fd	:	Suspected of damaging fertility. Suspected of damaging the unborn child.
H373	:	May cause damage to organs through prolonged or repeated exposure if swallowed.
H411	:	Toxic to aquatic life with long lasting effects.

The Turkish SDS has been prepared according to the Regulation on Safety Data Sheets for Hazardous Substances and Mixtures No. 29204.

#### Full text of other abbreviations

Acute Tox. :	Acute toxicity
Aquatic Chronic :	Long-term (chronic) aquatic hazard
Repr. :	Reproductive toxicity
STOT RE :	Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentra-

ardous substances and mixtures; Part I".

Public ORGANON

# Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.3	23.03.2020	2805574-00006	Date of first issue: 18.05.2018

tion; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB -Very Persistent and Very Bioaccumulative

## Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

Classification of the m	Classification procedure:	
Repr. 2	H361fd	Calculation method
STOT RE 2	H373	Calculation method
Aquatic Chronic 3	H412	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

TR / EN